Repare Therapeutics Newsroom

Express News | Repare Therapeutics Announces Agreement With the US National Cancer Institute to Advance the Development of Camonsertib

ReutersNov 12 07:05 ET

Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8

Moomoo NewsNov 11 08:31 ET · Ratings

Morgan Stanley Sticks to Their Hold Rating for Repare Therapeutics (RPTX)

TipRanksNov 11 08:21 ET · Ratings

Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsNov 8 10:31 ET · Ratings

Repare Therapeutics: Strong Financial Health and Promising Data Catalysts Justify Buy Rating With $10 Price Target

TipRanksNov 8 10:25 ET · Ratings

Express News | Repare Therapeutics - Entered Into Sales Agreement Relating to Common Shares Offered by Prospectus Supplement

ReutersNov 7 08:36 ET

Express News | Repare Therapeutics - May Offer, Sell Common Shares of up to $100 Mln From Time to Time

ReutersNov 7 08:35 ET

Repare Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 7 07:18 ET · Announcements

Repare Therapeutics | 8-K: Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

SECNov 7 07:13 ET

Repare Therapeutics 3Q Loss/Shr 81c >RPTX

Dow JonesNov 7 07:05 ET

Press Release: Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Dow JonesNov 7 07:05 ET

Express News | Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

ReutersNov 7 07:05 ET

Express News | Repare Therapeutics Q3 Income From Operations USD -36.372 Million

ReutersNov 7 07:05 ET

Repare Therapeutics Analyst Ratings

BenzingaOct 24 15:14 ET · Ratings

H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsOct 24 11:35 ET · Ratings

Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes

TipRanksOct 24 11:25 ET · Ratings

TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating

Moomoo NewsOct 24 08:31 ET · Ratings

Repare Therapeutics' Individualised Anaemia Management Trial Shows Promise

Yahoo FinanceOct 24 05:57 ET

Repare Therapeutics Presented Updated Data Highlighting The Benefits Of Its Individualized Schedule For Managing Anemia In Phase 1 MYTHIC Trial, Which Treated Patients With The Combination Of Lunresertib And Camonsertib

BenzingaOct 23 06:07 ET

Express News | Repare Therapeutics Inc - Analysis Shows Success in Mitigating Anemia, No Thrombocytopenia

ReutersOct 23 06:05 ET